

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

- 1-3. (Canceled).
4. (Previously Presented) The method of claim 23, for treatment of post-traumatic tissue injury.
5. (Previously Presented) The method of claim 4, wherein said post-traumatic tissue injury is caused by surgery.
6. (Previously Presented) The method of claim 23, for treatment of a thermic injury.
7. (Previously Presented) The method of claim 23, for treatment of a pathological condition with scar formation.
8. (Previously Presented) The method of claim 7, wherein said pathological condition with scar formation is caused by a vascular disease selected from the group consisting of bleeding and infarct.
9. (Previously Presented) The method of claim 7, wherein said pathological condition with scar formation is caused by a toxic influence.
10. (Previously Presented) The method of claim 7, wherein said pathological condition with scar formation is caused by cystic fibrosis.
- 11-22. (Canceled).

23. (Currently Amended) A method for reduction of adhesion formation ~~wherein comprising administering~~ a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is ~~administered to a patient in need of said treatment thereof, and~~ wherein:

the administration of the substance that inhibits a pro-inflammatory cytokine causes a reduction of adhesion formation;

~~wherein~~ said substance is a peptide derived from amino acid 12 to amino acid 40 of human lactoferrin comprising ²⁰Cys-Phe-X₁- X₂-X₃-X₄-X₅-X₆-X₇-Lys-Val-Arg³¹ (SEQ ID NO: 99), wherein X₁ is Gln or Ala; X₂ is Trp or Leu; X₃ is Gln, Lys, Orn, Ala, or Nle; X₄ is Arg, Lys, Ala; X₅ is Asn, Orn, Ala, or Nle; X₆ is Met or Leu; and X₇ is Arg or Lys; and said peptide is selected from the group consisting of SEQ ID NOS: 2-5, 8, 31-37, 47, 49, 51, 63, 65, 67, 70, 72-74, 80-83, 87-96 and 97.

24. (Previously Presented) The method of claim 23, wherein said substance is locally administered.

25. (Previously Presented) The method of claim 23, wherein said substance is systemically administered.

26-27. (Canceled).

28. (New) The method of claim 23, wherein said peptide is SEQ ID NO: 3 or SEQ ID NO: 37.